<p>TEL AVIV, Israel , Sept. 17, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the company will provide a corporate overview at...

<p>These data, together with positive preclinical NASH data previously presented, support the potential of VBL’s lecinoxoid pipeline Recently granted US patent provides patent protection for lecinoxoids treatment of fibrosis until at least November 2035 and supports potential partnering opportunitie...

<p>Conference Call and Webcast at 8:30am Eastern Time Today VBL is well capitalized, cash sufficient for more than 3 years, beyond key inflection points VBL continues development of VB-111 for Ovarian Cancer with the OVAL Phase 3 trial ongoing, and intends to explore VB-111 activity in additional</p...

<p>TEL AVIV, Israel , Aug. 01, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webca...

<p>Paper on Role of MOSPD2 in Metastatic Breast Cancer Published in International Journal of Cancer TEL AVIV, Israel , July 10, 2018 (GLOBE NEWSWIRE) --   VBL Therapeutics  (NASDAQ:VBLT) today announced the publication of data on the potential role of MOSPD2 in metastatic breast cancer in the</p> ...

<p>TEL AVIV, Israel , June 27, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics  (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer,  today announced the closing of its previously announced registered</p>...

<p>TEL AVIV, Israel , June 26, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics  (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer,  today announced that it has entered into definitive agreements with</p...

<p>TEL AVIV, Israel , June 05, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics  (NASDAQ:VBLT) today presented data on its novel MOSPD2 program in oncology and inflammation at the 2018 BIO International Convention in Boston, Massachusetts . &quot;Our research has shown that MOSPD2 plays a key role in the</...

<p>TEL AVIV, Israel , May 24, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that the Company will present an update on the OVAL Phase...

<p>Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , May 17, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq:VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced<...